Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
None
Dupilumab_Metastatic NSCLC

. For Phase 2, to determine the effect of adding IL-4Ra blockade to PD-(L)1 blocking agents in patients with relapsed/refractory NSCLC, who have progressed on prior PD-(L)1 agents

  • 0 views
  • 16 Oct, 2021
None
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

refractory non-small cell lung cancer (NSCLC), and advanced clear cell renal cell carcinoma (ccRCC). ABBV-CLS-484 will also be administered at the determined recommended dose in combination with a PD-1

  • 1 views
  • 19 Jun, 2021
  • 5 locations
None
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

Evaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab in non-small cell lung carcinoma and head and neck carcinoma patients.

stage iv non-small cell lung cancer
nivolumab
cancer chemotherapy
systemic therapy
EGFR
  • 20 views
  • 20 Oct, 2021
  • 19 locations
None
Atezolizumab and Cobimetinib in Treating Patients With Metastatic Recurrent or Refractory Non-small Cell Lung Cancer

This phase II trial studies how well atezolizumab and cobimetinib work in treating patients with non-small cell lung cancer that has spread to other places in the body (metastatic), has come back (recurrent), or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the …

pd-l1
ct scan
cancer
atezolizumab
lung cancer
  • 54 views
  • 24 Oct, 2021
  • 8 locations
None
Ph I/II Trial of Systemic VSV-IFN -NIS and Pembrolizumab in Refractory NSCLC and NEC

expansion portion will use one-sample binomial designs to assess the efficacy of the combination in patients with refractory NSCLC or NEC. The optimal dose (RP2D) determined in the dose escalation portion

pd-l1
stage iv non-small cell lung cancer
cancer treatment
cancer chemotherapy
immune checkpoint inhibitor
  • 0 views
  • 20 Oct, 2021
  • 1 location
None
Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients

Objectives: To determine the safety, tolerability, and efficacy of allogeneic PB103 in patients with IIIb/IV or refractory non-small-cell lung cancer

lung carcinoma
platelet count
serum bilirubin level
neutrophil count
  • 0 views
  • 03 Sep, 2021
  • 1 location
None
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer

clinical oncology, either a single format or given as combinations followed by surgery are effective in the treatment of relapsed and refractory non-small cell lung cancer patients.

lung cancer
carboplatin
cancer chemotherapy
docetaxel
  • 1 views
  • 25 Jan, 2021
  • 3 locations
None
Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).

advanced, refractory NSCLC and to detect a potential disease control signal when employed in combination with low dose chemotherapy (ie, paclitaxel), immunotherapy (ie, atezolizumab) in patients who

  • 0 views
  • 26 Jan, 2021
  • 3 locations
None
A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors

-small cell lung cancer (NSCLC) (Part B), and metastatic pancreatic cancer (Part C) to evaluate the safety and tolerability of CM-24 in combination with nivolumab. In Part C of the study nab-paclitaxel

brain metastases
cancer chemotherapy
serum pregnancy test
metastatic pancreatic adenocarcinoma
cancer
  • 0 views
  • 24 Oct, 2021
  • 6 locations
None
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

This is a two-agent, open-label, non-randomized, Phase 1/2 dose escalation and dose expansion study of combinatorial oral vorolanib plus infusional nivolumab in patients with Non-Small Cell Lung Cancer nave to checkpoint inhibitor therapy, Non-Small Cell Lung Cancer who have progressed on checkpoint inhibitor therapy, Small Cell Lung Cancer ( who …

pd-l1
chemotherapy regimen
vorolanib
bilateral oophorectomy
BRAF
  • 29 views
  • 27 Sep, 2021
  • 7 locations